Approval · Notice of Compliance 31434 · 2023
EXELON PATCH: Notice of Compliance 31434
Issued August 17, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31434
- Date
- August 17, 2023
- Company
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update to the Product Monograph (PM). Conversion of the Product Monograph to 2020 Format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON PATCH | Not yet assigned | — |
Medicinal ingredients
- RIVASTIGMINE 9 MG per PATCH
- RIVASTIGMINE 18 MG per PATCH
- RIVASTIGMINE 27 MG per PATCH